Study of Olutasidenib and Temozolomide in HGG
Public ClinicalTrials.gov record NCT06161974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of Olutasidenib with Temozolomide As Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations
Study identification
- NCT ID
- NCT06161974
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
- Astrocytoma
- Astrocytoma, Grade III
- Astrocytoma, Grade IV
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
- High Grade Glioma
- IDH1 Mutation
- IDH1 R132
- IDH1 R132C
- IDH1 R132G
- IDH1 R132H
- IDH1 R132L
- IDH1 R132S
- Metastatic Brain Tumor
- Oligodendroglioma
- Spinal Tumor
- Thalamus Tumor
- WHO Grade III Glioma
- WHO Grade IV Glioma
Interventions
- Olutasidenib + TMZ Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 39 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2025
- Primary completion
- May 31, 2029
- Completion
- May 31, 2035
- Last update posted
- Feb 20, 2025
2025 – 2035
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Colorado | Aurora | Colorado | 80045 | Not yet recruiting |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | Not yet recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | Not yet recruiting |
| Susan Chi | Boston | Massachusetts | 02215 | Not yet recruiting |
| Duke University Health System | Durham | North Carolina | 27708 | Not yet recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | Recruiting |
| Nationwide Children's Hospital | Columbus | Ohio | 43235 | Not yet recruiting |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | Not yet recruiting |
| Texas Children's Hospital | Houston | Texas | 77030 | Not yet recruiting |
| Seattle Children's Hospital | Seattle | Washington | 98105 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06161974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06161974 live on ClinicalTrials.gov.